The GSK oncology products it has sold on to Novartis were ... Other drugs in the portfolio include Votrient, for renal cell carcinoma, Promacta for thrombocytopenia, HER2+ metastatic breast ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

Pharma major GSK (LSE: GSK) on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

“Emma led the executive team and the wider organisation to deliver continued, improved operating performance in 2024, with GSK’s reshaped product portfolio demonstrating both strength and ...

Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio The latest announcement is out from GlaxoSmithKline ( (GB:GSK)). GSK announced ...

March 24 (Reuters) - GSK (GSK.L), opens new tab on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's asthama drug Nucala as an ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.